HD Insights™

Vol. 4 - Spring 2013

Issue link: http://www.e-digitaleditions.com/i/118112

Contents of this Issue

Navigation

Page 0 of 11

HDInsights TM periodical A Huntington disease research Issue No 4 -- Spring 2013 Meet the Compound Information on Huntexil and overviews of the MermaiHD and HART trials, with commentary from MermaiHD lead author Dr. Justo Garcia de Yebenes. Page 4 HD Research in Japan Dr. Hitoshi Okazawa discusses past and current research in Japan, as well as promising research avenues for the future. Page 7 Research Round-Up Dr. Lise Munsie reviews the latest HD developments in basic, pre-clinical, and clinical research. Page 5 Status Report: Clinical Trials At a glance updates on current clinical trials in HD. Page 6 Meet the Investigator VITAL SIGNS NAME: Michael Hayden, CM, OBC, MB, ChB, PhD, FRCP(C), FRSC CURRENT POSITION: President of Global Research and Development and Chief Scientific Officer at Teva Pharmaceuticals OTHER POSITIONS: Killam Professor of Medical Genetics at the University of British Columbia, Canada Research Chair in Human Genetics and Molecular Medicine, Founder and director for the Center for Molecular Medicine and Therapeutics in Vancouver, Canada, Program director of the Translational Laboratory in Genetic Medicine at the National University of Singapore, Founder of NeuroVir, Xenon Genetics, Inc., and Aspreva Pharmaceuticals, Inc EDUCATION: MB, ChB, PhD, University of Cape Town, Post-doctoral fellowship, Harvard University HOBBIES: Collecting art, photography, and enjoying creativity in other domains.  FAVORITE ARTIST: Ben Shahn, who was born in Lithuania and became a social activist in America.  He is known for his works of social realism. HD Insights, Vol. 4 Dr. Michael Hayden Dr. Michael Hayden was recently appointed as the President of Global Research and Development and Chief Scientific Officer at Teva Pharmaceuticals. Dr. Hayden is the most highly cited author in Huntington disease. He is the founder and director of the Centre for Molecular Medicine and Therapeutics in Vancouver, and founder of three biotechnology companies (NeuroVir, Xenon Genetics, and Aspreva Pharmaceuticals). Copyright © Huntington Study Group 2013. All rights reserved. 1

Articles in this issue

Archives of this issue

view archives of HD Insights™ - Vol. 4 - Spring 2013